KIT/PDGFRA inhibitors such as imatinib mesylate are the mainstay of medical treatment for advanced GIST but they are not curative due in part to secondary mutations interfering with drug action [6] or lack of dependence of cancer-initiating cells on KIT/PDGFRA signaling [8]. Here, PDGFRA is linked to cancer.